<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39339912</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 Variants from Long-Term, Persistently Infected Immunocompromised Patients Have Altered Syncytia Formation, Temperature-Dependent Replication, and Serum Neutralizing Antibody Escape.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1436</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091436</ELocationID><Abstract><AbstractText>SARS-CoV-2 infection of immunocompromised individuals often leads to prolonged detection of viral RNA and infectious virus in nasal specimens, presumably due to the lack of induction of an appropriate adaptive immune response. Mutations identified in virus sequences obtained from persistently infected patients bear signatures of immune evasion and have some overlap with sequences present in variants of concern. We characterized virus isolates obtained greater than 100 days after the initial COVID-19 diagnosis from two COVID-19 patients undergoing immunosuppressive cancer therapy, wand compared them to an isolate from the start of the infection. Isolates from an individual who never mounted an antibody response specific to SARS-CoV-2 despite the administration of convalescent plasma showed slight reductions in plaque size and some showed temperature-dependent replication attenuation on human nasal epithelial cell culture compared to the virus that initiated infection. An isolate from another patient-who did mount a SARS-CoV-2 IgM response-showed temperature-dependent changes in plaque size as well as increased syncytia formation and escape from serum-neutralizing antibodies. Our results indicate that not all virus isolates from immunocompromised COVID-19 patients display clear signs of phenotypic change, but increased attention should be paid to monitoring virus evolution in this patient population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wouters</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sachithanandham</LastName><ForeName>Jaiprasath</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akin</LastName><ForeName>Elgin</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8824-8809</Identifier><AffiliationInfo><Affiliation>W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pieterse</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fall</LastName><ForeName>Amary</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6890-7915</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truong</LastName><ForeName>Thao T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bard</LastName><ForeName>Jennifer Dien</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5439-4218</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, The George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mostafa</LastName><ForeName>Heba H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pekosz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3248-1761</Identifier><AffiliationInfo><Affiliation>W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N272201400007C</GrantID><Agency>National Insitutes of Health</Agency><Country /></Grant><Grant><GrantID>N75N03021C00045</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>W911QY2090012</GrantID><Agency>Department of Defense</Agency><Country /></Grant><Grant><GrantID>75D30121C11061</GrantID><Agency>Centers for Disease Control</Agency><Country /></Grant><Grant><GrantID>U54 CA260492</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N/A</GrantID><Agency>Bloomberg Philanthropies</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>Richard Eliasberg Family Foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="Y">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015726" MajorTopicYN="Y">Giant Cells</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057131" MajorTopicYN="N">Immune Evasion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013696" MajorTopicYN="N">Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immunocompromised host</Keyword><Keyword MajorTopicYN="N">neutralizing antibody escape</Keyword><Keyword MajorTopicYN="N">syncytia</Keyword><Keyword MajorTopicYN="N">virus evolution</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339912</ArticleId><ArticleId IdType="pmc">PMC11437501</ArticleId><ArticleId IdType="doi">10.3390/v16091436</ArticleId><ArticleId IdType="pii">v16091436</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clark S.A., Clark L.E., Pan J., Coscia A., McKay L.G.A., Shankar S., Johnson R.I., Brusic V., Choudhary M.C., Regan J., et al. SARS-CoV-2 Evolution in an Immunocompromised Host Reveals Shared Neutralization Escape Mechanisms. Cell. 2021;184:2605–2617.e18. doi: 10.1016/j.cell.2021.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.027</ArticleId><ArticleId IdType="pmc">PMC7962548</ArticleId><ArticleId IdType="pubmed">33831372</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Guo Y., Iketani S., Nair M.S., Li Z., Mohri H., Wang M., Yu J., Bowen A.D., Chang J.Y., et al. Antibody Evasion by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608:603–608. doi: 10.1038/s41586-022-05053-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05053-w</ArticleId><ArticleId IdType="pmc">PMC9385487</ArticleId><ArticleId IdType="pubmed">35790190</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto S.P., Day T., Arino J., Colijn C., Dushoff J., Li M., Mechai S., Van Domselaar G., Wu J., Earn D.J.D., et al. The Origins and Potential Future of SARS-CoV-2 Variants of Concern in the Evolving COVID-19 Pandemic. Curr. Biol. 2021;31:R918–R929. doi: 10.1016/j.cub.2021.06.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2021.06.049</ArticleId><ArticleId IdType="pmc">PMC8220957</ArticleId><ArticleId IdType="pubmed">34314723</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun K.M., Moreno G.K., Wagner C., Accola M.A., Rehrauer W.M., Baker D.A., Koelle K., O’Connor D.H., Bedford T., Friedrich T.C., et al. Acute SARS-CoV-2 Infections Harbor Limited within-Host Diversity and Transmit via Tight Transmission Bottlenecks. PLoS Pathog. 2021;17:e1009849. doi: 10.1371/journal.ppat.1009849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009849</ArticleId><ArticleId IdType="pmc">PMC8412271</ArticleId><ArticleId IdType="pubmed">34424945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lythgoe K.A., Hall M., Ferretti L., de Cesare M., MacIntyre-Cockett G., Trebes A., Andersson M., Otecko N., Wise E.L., Moore N., et al. SARS-CoV-2 within-Host Diversity and Transmission. Science. 2021;372:eabg0821. doi: 10.1126/science.abg0821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg0821</ArticleId><ArticleId IdType="pmc">PMC8128293</ArticleId><ArticleId IdType="pubmed">33688063</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi B., Choudhary M.C., Regan J., Sparks J.A., Padera R.F., Qiu X., Solomon I.H., Kuo H.-H., Boucau J., Bowman K., et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N. Engl. J. Med. 2020;383:2291–2293. doi: 10.1056/NEJMc2031364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031364</ArticleId><ArticleId IdType="pmc">PMC7673303</ArticleId><ArticleId IdType="pubmed">33176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp S.A., Collier D.A., Datir R.P., Ferreira I.A.T.M., Gayed S., Jahun A., Hosmillo M., Rees-Spear C., Mlcochova P., Lumb I.U., et al. SARS-CoV-2 Evolution during Treatment of Chronic Infection. Nature. 2021;592:277–282. doi: 10.1038/s41586-021-03291-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03291-y</ArticleId><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch M., Macori G., Fanning S., O’Regan E., Hunt E., O’Callaghan D., McCullagh B., Jennings C., Fortune A. Genomic Evolution of SARS-CoV-2 Virus in Immunocompromised Patient, Ireland. Emerg. Infect. Dis. 2021;27:2499–2501. doi: 10.3201/eid2709.211159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2709.211159</ArticleId><ArticleId IdType="pmc">PMC8386806</ArticleId><ArticleId IdType="pubmed">34161223</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong T.T., Ryutov A., Pandey U., Yee R., Goldberg L., Bhojwani D., Aguayo-Hiraldo P., Pinsky B.A., Pekosz A., Shen L., et al. Increased Viral Variants in Children and Young Adults with Impaired Humoral Immunity and Persistent SARS-CoV-2 Infection: A Consecutive Case Series. EBioMedicine. 2021;67:103355. doi: 10.1016/j.ebiom.2021.103355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103355</ArticleId><ArticleId IdType="pmc">PMC8072072</ArticleId><ArticleId IdType="pubmed">33915337</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnleitner S.T., Prelog M., Sonnleitner S., Hinterbichler E., Halbfurter H., Kopecky D.B.C., Almanzar G., Koblmüller S., Sturmbauer C., Feist L., et al. Cumulative SARS-CoV-2 Mutations and Corresponding Changes in Immunity in an Immunocompromised Patient Indicate Viral Evolution within the Host. Nat. Commun. 2022;13:2560. doi: 10.1038/s41467-022-30163-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30163-4</ArticleId><ArticleId IdType="pmc">PMC9090742</ArticleId><ArticleId IdType="pubmed">35538074</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris C.P., Luo C.H., Sachithanandham J., Li M., Schwartz M., Gaston D.C., Gniazdowski V., Giraldo-Castillo N., Amadi A., Norton J.M., et al. Large Scale SARS-CoV-2 Molecular Testing and Genomic Surveillance Reveal Prolonged Infections, Protracted RNA Shedding, and Viral Reinfections. Front. Cell Infect. Microbiol. 2022;12:809407. doi: 10.3389/fcimb.2022.809407.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.809407</ArticleId><ArticleId IdType="pmc">PMC9035932</ArticleId><ArticleId IdType="pubmed">35480235</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy K.R., Rennick L.J., Nambulli S., Robinson-McCarthy L.R., Bain W.G., Haidar G., Paul Duprex W. Recurrent Deletions in the SARS-CoV-2 Spike Glycoprotein Drive Antibody Escape. Science. 2021;371:1139–1142. doi: 10.1126/science.abf6950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf6950</ArticleId><ArticleId IdType="pmc">PMC7971772</ArticleId><ArticleId IdType="pubmed">33536258</ArticleId></ArticleIdList></Reference><Reference><Citation>Raglow Z., Surie D., Chappell J.D., Zhu Y., Martin E.T., Kwon J.H., Frosch A.E., Mohamed A., Gilbert J., Bendall E.E., et al. SARS-CoV-2 Shedding and Evolution in Patients Who Were Immunocompromised during the Omicron Period: A Multicentre, Prospective Analysis. Lancet Microbe. 2024;5:E235–E246. doi: 10.1016/S2666-5247(23)00336-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00336-1</ArticleId><ArticleId IdType="pubmed">38286131</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M., Tate M., Lloyd O., Maraolo A.E., Schafers J., Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV Viral Load Dynamics, Duration of Viral Shedding, and Infectiousness: A Systematic Review and Meta-Analysis. Lancet Microbe. 2021;2:e13–e22. doi: 10.1016/S2666-5247(20)30172-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30172-5</ArticleId><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisblum Y., Schmidt F., Zhang F., DaSilva J., Poston D., Lorenzi J.C.C., Muecksch F., Rutkowska M., Hoffmann H.H., Michailidis E., et al. Escape from Neutralizing Antibodies 1 by SARS-CoV-2 Spike Protein Variants. Elife. 2020;9:e61312. doi: 10.7554/eLife.61312.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.61312</ArticleId><ArticleId IdType="pmc">PMC7723407</ArticleId><ArticleId IdType="pubmed">33112236</ArticleId></ArticleIdList></Reference><Reference><Citation>Karaba A.H., Zhu X., Liang T., Wang K.H., Rittenhouse A.G., Akinde O., Eby Y., Ruff J.E., Blankson J.N., Abedon A.T., et al. A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies against Variants of Concern in Solid Organ Transplant Recipients. Am. J. Transplant. 2022;22:1253–1260. doi: 10.1111/ajt.16933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16933</ArticleId><ArticleId IdType="pmc">PMC8983554</ArticleId><ArticleId IdType="pubmed">34951746</ArticleId></ArticleIdList></Reference><Reference><Citation>Karaba A.H., Johnston T.S., Aytenfisu T.Y., Akinde O., Eby Y., Ruff J.E., Abedon A.T., Alejo J.L., Blankson J.N., Cox A.L., et al. A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients with Suboptimal Vaccine Response. Transplantation. 2022;106:1440–1444. doi: 10.1097/TP.0000000000004140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004140</ArticleId><ArticleId IdType="pmc">PMC9213052</ArticleId><ArticleId IdType="pubmed">35417115</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederer K., Bettini E., Parvathaneni K., Painter M.M., Agarwal D., Lundgreen K.A., Weirick M., Muralidharan K., Castaño D., Goel R.R., et al. Germinal Center Responses to SARS-CoV-2 MRNA Vaccines in Healthy and Immunocompromised Individuals. Cell. 2022;185:1008–1024.e15. doi: 10.1016/j.cell.2022.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.027</ArticleId><ArticleId IdType="pmc">PMC8808747</ArticleId><ArticleId IdType="pubmed">35202565</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Zhao J., Han M., Meng F., Zhou J. SARS-CoV-2 Infection in Immunocompromised Patients: Humoral versus Cell-Mediated Immunity. J. Immunother. Cancer. 2020;8:e000862. doi: 10.1136/jitc-2020-000862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-000862</ArticleId><ArticleId IdType="pmc">PMC7431770</ArticleId><ArticleId IdType="pubmed">32727811</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer E.M., Babiker A., Adelman M.W., Allman B., Key A., Kleinhenz J.M., Langsjoen R.M., Nguyen P.-V., Onyechi I., Sherman J.D., et al. SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients. N. Engl. J. Med. 2022;386:2436–2438. doi: 10.1056/NEJMc2202861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2202861</ArticleId><ArticleId IdType="pmc">PMC9202319</ArticleId><ArticleId IdType="pubmed">35675197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S., Karim F., Lustig G., San J.E., Hermanus T., Tegally H., Snyman J., Moyo-Gwete T., Wilkinson E., Bernstein M., et al. SARS-CoV-2 Prolonged Infection during Advanced HIV Disease Evolves Extensive Immune Escape. Cell Host Microbe. 2022;30:154–162.e5. doi: 10.1016/j.chom.2022.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.01.005</ArticleId><ArticleId IdType="pmc">PMC8758318</ArticleId><ArticleId IdType="pubmed">35120605</ArticleId></ArticleIdList></Reference><Reference><Citation>Meera C., Susan H., Gavin D., Christina A., Wendy B., Neil F., Erik V., Nick L., Andrew R.J.B. Investigation of Novel SARS-COV-2 Variant Variant of Concern 202012/01 Detection of an Epidemiological Cluster Associated with a New Variant of Concern Nomenclature of Variants in the UK Current Epidemiological Findings. Public Health England; London, UK: 2020. Published December 2020, PHE Gateway Number: GW-1824 1–11.</Citation></Reference><Reference><Citation>Corey L., Beyrer C., Cohen M.S., Michael N.L., Bedford T., Rolland M. SARS-CoV-2 Variants in Patients with Immunosuppression. N. Engl. J. Med. 2021;385:562–566. doi: 10.1056/NEJMsb2104756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsb2104756</ArticleId><ArticleId IdType="pmc">PMC8494465</ArticleId><ArticleId IdType="pubmed">34347959</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupferschmidt K. Where Did ‘Weird’ Omicron Come From? Science. 2021;374:1179. doi: 10.1126/science.acx9738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.acx9738</ArticleId><ArticleId IdType="pubmed">34855502</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Reiche A.S., Alshammary H., Schaefer S., Patel G., Polanco J., Carreño J.M., Amoako A.A., Rooker A., Cognigni C., Floda D., et al. Sequential Intrahost Evolution and Onward Transmission of SARS-CoV-2 Variants. Nat. Commun. 2023;14:3235. doi: 10.1038/s41467-023-38867-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38867-x</ArticleId><ArticleId IdType="pmc">PMC10239218</ArticleId><ArticleId IdType="pubmed">37270625</ArticleId></ArticleIdList></Reference><Reference><Citation>Weigang S., Fuchs J., Zimmer G., Schnepf D., Kern L., Beer J., Luxenburger H., Ankerhold J., Falcone V., Kemming J., et al. Within-Host Evolution of SARS-CoV-2 in an Immunosuppressed COVID-19 Patient as a Source of Immune Escape Variants. Nat. Commun. 2021;12:6405. doi: 10.1038/s41467-021-26602-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26602-3</ArticleId><ArticleId IdType="pmc">PMC8568958</ArticleId><ArticleId IdType="pubmed">34737266</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaki L., Weigang S., Kern L., Kramme S., Wrobel A.G., Grawitz A.B., Nawrath P., Martin S.R., Dähne T., Beer J., et al. Total Escape of SARS-CoV-2 from Dual Monoclonal Antibody Therapy in an Immunocompromised Patient. Nat. Commun. 2023;14:1999. doi: 10.1038/s41467-023-37591-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37591-w</ArticleId><ArticleId IdType="pmc">PMC10085998</ArticleId><ArticleId IdType="pubmed">37037847</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride J.A., Striker R. Imbalance in the Game of T Cells: What Can the CD4/CD8 T-Cell Ratio Tell Us about HIV and Health? PLoS Pathog. 2017;13:e1006624. doi: 10.1371/journal.ppat.1006624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006624</ArticleId><ArticleId IdType="pmc">PMC5667733</ArticleId><ArticleId IdType="pubmed">29095912</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama S., Nao N., Shirato K., Kawase M., Saito S., Takayama I., Nagata N., Sekizuka T., Katoh H., Kato F., et al. Enhanced Isolation of SARS-CoV-2 by TMPRSS2-Expressing Cells. Proc. Natl. Acad. Sci. USA. 2020;117:7001–7003. doi: 10.1073/pnas.2002589117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2002589117</ArticleId><ArticleId IdType="pmc">PMC7132130</ArticleId><ArticleId IdType="pubmed">32165541</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon S., Anaya E., Sachithanandham J., Pinsky B., Sullivan D., Pekosz A. Convergent Evolution of A-Lineage (Clade 19B) SARS-CoV-2 Spike Sequences with B-Lineage 1 Variants of Concern Affects Virus Replication in a Temperature-Dependent Manner on Human 2 Nasal Epithelial Cell Cultures 3. bioRxiv. 2023 doi: 10.1101/2023.03.03.531067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.03.03.531067</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick J.D., Beer M.A., Pekosz A. Early Transcriptional Responses of Human Nasal Epithelial Cells to Infection with Influenza A and SARS-CoV-2 Virus Differ and Are Influenced by Physiological Temperature. Pathogens. 2023;12:480. doi: 10.3390/pathogens12030480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens12030480</ArticleId><ArticleId IdType="pmc">PMC10051809</ArticleId><ArticleId IdType="pubmed">36986402</ArticleId></ArticleIdList></Reference><Reference><Citation>Fall A., Eldesouki R.E., Sachithanandham J., Morris C.P., Norton J.M., Gaston D.C., Forman M., Abdullah O., Gallagher N., Li M., et al. The Displacement of the SARS-CoV-2 Variant Delta with Omicron: An Investigation of Hospital Admissions and Upper Respiratory Viral Loads. EBioMedicine. 2022;79:104008. doi: 10.1016/j.ebiom.2022.104008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104008</ArticleId><ArticleId IdType="pmc">PMC9020587</ArticleId><ArticleId IdType="pubmed">35460989</ArticleId></ArticleIdList></Reference><Reference><Citation>Thielen P.M., Wohl S., Mehoke T., Ramakrishnan S., Kirsche M., Falade-Nwulia O., Trovão N.S., Ernlund A., Howser C., Sadowski N., et al. Genomic Diversity of SARS-CoV-2 during Early Introduction into the Baltimore-Washington Metropolitan Area. JCI Insight. 2021;6:e144350. doi: 10.1172/jci.insight.144350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.144350</ArticleId><ArticleId IdType="pmc">PMC8026189</ArticleId><ArticleId IdType="pubmed">33749660</ArticleId></ArticleIdList></Reference><Reference><Citation>REED L.J., Muench H. A Simple Method of Estimating Fifty Per Cent Endpoints12. Am. J. Epidemiol. 1938;27:493–497. doi: 10.1093/oxfordjournals.aje.a118408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Beck E.J., Laeyendecker O., Eby Y., Tobian A.A.R., Caturegli P., Wouters C., Chiklis G.R., Block W., McKie R.O., et al. Convalescent Plasma with a High Level of Virus-Specific Antibody Effectively Neutralizes SARS-CoV-2 Variants of Concern. Blood Adv. 2022;6:3678–3683. doi: 10.1182/bloodadvances.2022007410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022007410</ArticleId><ArticleId IdType="pmc">PMC9023079</ArticleId><ArticleId IdType="pubmed">35443020</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon O., Brosnan M.K., Yoon S., Jung D., Littlefield K., Ganesan A., Caputo C.A., Li M., Morgenlander W.R., Henson S.N., et al. Pharmacokinetics of High-Titer Anti–SARS-CoV-2 Human Convalescent Plasma in High-Risk Children. JCI Insight. 2022;7:e151518. doi: 10.1172/jci.insight.151518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.151518</ArticleId><ArticleId IdType="pmc">PMC8855821</ArticleId><ArticleId IdType="pubmed">34855624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitoshi N., Ken-ichi Y., Jun-ichi M. Efficient Selection for High-Expression Transfectants with a Novel Eukaryotic Vector. Gene. 1991;108:193–199. doi: 10.1016/0378-1119(91)90434-D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0378-1119(91)90434-D</ArticleId><ArticleId IdType="pubmed">1660837</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodcroft E. CoVariants Overview of Variants/Mutations.  [(accessed on 4 December 2021)].  Available online:  https://covariants.org/variants.</Citation></Reference><Reference><Citation>Zhou D., Dejnirattisai W., Supasa P., Liu C., Mentzer A.J., Ginn H.M., Zhao Y., Duyvesteyn H.M.E., Tuekprakhon A., Nutalai R., et al. Evidence of Escape of SARS-CoV-2 Variant B.1.351 from Natural and Vaccine-Induced Sera. Cell. 2021;184:2348–2361.e6. doi: 10.1016/j.cell.2021.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.037</ArticleId><ArticleId IdType="pmc">PMC7901269</ArticleId><ArticleId IdType="pubmed">33730597</ArticleId></ArticleIdList></Reference><Reference><Citation>Harari S., Tahor M., Rutsinsky N., Meijer S., Miller D., Henig O., Halutz O., Levytskyi K., Ben-Ami R., Adler A., et al. Drivers of Adaptive Evolution during Chronic SARS-CoV-2 Infections. Nat. Med. 2022;28:1501–1508. doi: 10.1038/s41591-022-01882-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01882-4</ArticleId><ArticleId IdType="pmc">PMC9307477</ArticleId><ArticleId IdType="pubmed">35725921</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed A.M., Taha T.Y., Khalid M.M., Tabata T., Chen I.P., Sreekumar B., Chen P.-Y., Hayashi J.M., Soczek K.M., Ott M., et al. Rapid Assessment of SARS-CoV-2 Evolved Variants Using Virus-like Particles. Science. 2021;374:1626–1632. doi: 10.1126/science.abl6184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl6184</ArticleId><ArticleId IdType="pmc">PMC9005165</ArticleId><ArticleId IdType="pubmed">34735219</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemudryi A., Nemudraia A., Wiegand T., Nichols J., Snyder D.T., Hedges J.F., Cicha C., Lee H., Vanderwood K.K., Bimczok D., et al. SARS-CoV-2 Genomic Surveillance Identifies Naturally Occurring Truncation of ORF7a That Limits Immune Suppression. Cell Rep. 2021;35:109197. doi: 10.1016/j.celrep.2021.109197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109197</ArticleId><ArticleId IdType="pmc">PMC8118641</ArticleId><ArticleId IdType="pubmed">34043946</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N., Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D., et al. Nucleocapsid Mutations in SARS-CoV-2 Augment Replication and Pathogenesis. PLoS Pathog. 2022;18:e1010627. doi: 10.1371/journal.ppat.1010627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010627</ArticleId><ArticleId IdType="pmc">PMC9275689</ArticleId><ArticleId IdType="pubmed">35728038</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H., Xing N., Meng K., Fu B., Xue W., Dong P., Tang W., Xiao Y., Liu G., Luo H., et al. Nucleocapsid Mutations R203K/G204R Increase the Infectivity, Fitness, and Virulence of SARS-CoV-2. Cell Host Microbe. 2021;29:1788–1801.e6. doi: 10.1016/j.chom.2021.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.11.005</ArticleId><ArticleId IdType="pmc">PMC8590493</ArticleId><ArticleId IdType="pubmed">34822776</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Nadeau S., Yared M., Voinov P., Xie N., Roemer C., Stadler T. CoV-Spectrum: Analysis of Globally Shared SARS-CoV-2 Data to Identify and Characterize New Variants. Bioinformatics. 2022;38:1735–1737. doi: 10.1093/bioinformatics/btab856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btab856</ArticleId><ArticleId IdType="pmc">PMC8896605</ArticleId><ArticleId IdType="pubmed">34954792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Sarma P., Kaur H., Prajapat M. Clinically Relevant Cell Culture Models and Their Significance in Isolation, Pathogenesis, Vaccine Development, Repurposing and Screening of New Drugs for SARS-CoV-2: A Systematic Review. Tissue Cell. 2021;70:101497. doi: 10.1016/j.tice.2021.101497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tice.2021.101497</ArticleId><ArticleId IdType="pmc">PMC7836970</ArticleId><ArticleId IdType="pubmed">33550034</ArticleId></ArticleIdList></Reference><Reference><Citation>Laporte M., Raeymaekers V., van Berwaer R., Vandeput J., Marchand-Casas I., Thibaut H.J., van Looveren D., Martens K., Hoffmann M., Maes P., et al. The SARS-CoV-2 and Other Human Coronavirus Spike Proteins Are Fine-Tuned towards Temperature and Proteases of the Human Airways. PLoS Pathog. 2021;17:e1009500. doi: 10.1371/journal.ppat.1009500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009500</ArticleId><ArticleId IdType="pmc">PMC8061995</ArticleId><ArticleId IdType="pubmed">33886690</ArticleId></ArticleIdList></Reference><Reference><Citation>V’kovski P., Gultom M., Kelly J.N., Steiner S., Russeil J., Mangeat B., Cora E., Pezoldt J., Holwerda M., Kratzel A., et al. Disparate Temperature-Dependent Virus–Host Dynamics for SARS-CoV-2 and SARS-CoV in the Human Respiratory Epithelium. PLoS Biol. 2021;19:e3001158. doi: 10.1371/journal.pbio.3001158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001158</ArticleId><ArticleId IdType="pmc">PMC8032198</ArticleId><ArticleId IdType="pubmed">33780434</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Liu J., Johnson B.A., Xia H., Ku Z., Schindewolf C., Widen S.G., An Z., Weaver S.C., Menachery V.D., et al. Delta Spike P681R Mutation Enhances SARS-CoV-2 Fitness over Alpha Variant. Cell Rep. 2022;39:110829. doi: 10.1016/j.celrep.2022.110829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110829</ArticleId><ArticleId IdType="pmc">PMC9050581</ArticleId><ArticleId IdType="pubmed">35550680</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock T.P., Brown J.C., Zhou J., Thakur N., Sukhova K., Newman J., Kugathasan R., Yan A.W.C., Furnon W., De Lorenzo G., et al. The Altered Entry Pathway and Antigenic Distance of the SARS-CoV-2 Omicron Variant Map to Separate Domains of Spike Protein. bioRxiv. 2021. bioRxiv:2021.12.31.474653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.31.474653</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer W.A., King L.S., Lane A.P., Pekosz A. Restricted Replication of the Live Attenuated Influenza A Virus Vaccine during Infection of Primary Differentiated Human Nasal Epithelial Cells. Vaccine. 2015;33:4495–4504. doi: 10.1016/j.vaccine.2015.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.07.023</ArticleId><ArticleId IdType="pmc">PMC4547880</ArticleId><ArticleId IdType="pubmed">26196325</ArticleId></ArticleIdList></Reference><Reference><Citation>Canaday L.M., Resnick J.D., Liu H., Powell H., McCoy A.M., Nguyen D., Pekosz A. HA and M2 Sequences Alter the Replication of 2013–16 H1 Live Attenuated Influenza Vaccine Infection in Human Nasal Epithelial Cell Cultures. Vaccine. 2022;40:4544–4553. doi: 10.1016/j.vaccine.2022.05.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.05.088</ArticleId><ArticleId IdType="pubmed">35718589</ArticleId></ArticleIdList></Reference><Reference><Citation>Wohlgemuth N., Ye Y., Fenstermacher K.J., Liu H., Lane A.P., Pekosz A. The M2 Protein of Live, Attenuated Influenza Vaccine Encodes a Mutation That Reduces Replication in Human Nasal Epithelial Cells. Vaccine. 2017;35:6691–6699. doi: 10.1016/j.vaccine.2017.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.10.018</ArticleId><ArticleId IdType="pmc">PMC5696008</ArticleId><ArticleId IdType="pubmed">29079099</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., Datir R., Choi J., Baker S., Dougan G., Hess C., Kingston N., Lehner P.J., Lyons P.A., Matheson N.J., et al. SARS-CoV-2 Spike N-Terminal Domain Modulates TMPRSS2-Dependent Viral Entry and Fusogenicity. Cell Rep. 2022;40:111220. doi: 10.1016/j.celrep.2022.111220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111220</ArticleId><ArticleId IdType="pmc">PMC9346021</ArticleId><ArticleId IdType="pubmed">35963244</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S., Harvey W.T., Lytras S., Mohamed A., Gallo G., et al. Recurrent Emergence of SARS-CoV-2 Spike Deletion H69/V70 and Its Role in the Alpha Variant B.1.1.7. Cell Rep. 2021;35:109292. doi: 10.1016/j.celrep.2021.109292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109292</ArticleId><ArticleId IdType="pmc">PMC8185188</ArticleId><ArticleId IdType="pubmed">34166617</ArticleId></ArticleIdList></Reference><Reference><Citation>Papa G., Mallery D.L., Albecka A., Welch L.G., Cattin-Ortolá J., Luptak J., Paul D., McMahon H.T., Goodfellow I.G., Carter A., et al. Furin Cleavage of SARS-CoV-2 Spike Promotes but Is Not Essential for Infection and Cell-Cell Fusion. PLoS Pathog. 2021;17:e1009246. doi: 10.1371/journal.ppat.1009246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009246</ArticleId><ArticleId IdType="pmc">PMC7861537</ArticleId><ArticleId IdType="pubmed">33493182</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Wang J., Jian F., Xiao T., Song W., Yisimayi A., Huang W., Li Q., Wang P., An R., et al. Omicron Escapes the Majority of Existing SARS-CoV-2 Neutralizing Antibodies. Nature. 2022;602:657–663. doi: 10.1038/s41586-021-04385-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04385-3</ArticleId><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney A.J., Loes A.N., Crawford K.H.D., Starr T.N., Malone K.D., Chu H.Y., Bloom J.D. Comprehensive Mapping of Mutations in the SARS-CoV-2 Receptor-Binding Domain That Affect Recognition by Polyclonal Human Plasma Antibodies. Cell Host Microbe. 2021;29:463–476.e6. doi: 10.1016/j.chom.2021.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.02.003</ArticleId><ArticleId IdType="pmc">PMC7869748</ArticleId><ArticleId IdType="pubmed">33592168</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney A.J., Starr T.N., Barnes C.O., Weisblum Y., Schmidt F., Caskey M., Gaebler C., Cho A., Agudelo M., Finkin S., et al. Mapping Mutations to the SARS-CoV-2 RBD That Escape Binding by Different Classes of Antibodies. Nat. Commun. 2021;12:4196. doi: 10.1038/s41467-021-24435-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24435-8</ArticleId><ArticleId IdType="pmc">PMC8263750</ArticleId><ArticleId IdType="pubmed">34234131</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajah M.M., Hubert M., Bishop E., Saunders N., Robinot R., Grzelak L., Planas D., Dufloo J., Gellenoncourt S., Bongers A., et al. SARS-CoV-2 Alpha, Beta, and Delta Variants Display Enhanced Spike-mediated Syncytia Formation. EMBO J. 2021;40:e108944. doi: 10.15252/embj.2021108944.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021108944</ArticleId><ArticleId IdType="pmc">PMC8646911</ArticleId><ArticleId IdType="pubmed">34601723</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T.N., Greaney A.J., Hannon W.W., Loes A.N., Hauser K., Dillen J.R., Ferri E., Farrell A.G., Dadonaite B., McCallum M., et al. Shifting Mutational Constraints in the SARS-CoV-2 Receptor-Binding Domain during Viral Evolution. Science. 2022;377:420–424. doi: 10.1126/science.abo7896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abo7896</ArticleId><ArticleId IdType="pmc">PMC9273037</ArticleId><ArticleId IdType="pubmed">35762884</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson S.A.J., Richter A., Casey A., Osman H., Mirza J.D., Stockton J., Quick J., Ratcliffe L., Sparks N., Cumley N., et al. Recurrent SARS-CoV-2 Mutations in Immunodeficient Patients. Virus Evol. 2022;8:veac050. doi: 10.1093/ve/veac050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veac050</ArticleId><ArticleId IdType="pmc">PMC9384748</ArticleId><ArticleId IdType="pubmed">35996593</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh K.C.M., Tang C.K., Norton D.C., Gan E.S., Tan H.C., Sun B., Syenina A., Yousuf A., Ong X.M., Kamaraj U.S., et al. Molecular Determinants of Plaque Size as an Indicator of Dengue Virus Attenuation. Sci. Rep. 2016;6:26100. doi: 10.1038/srep26100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep26100</ArticleId><ArticleId IdType="pmc">PMC4868997</ArticleId><ArticleId IdType="pubmed">27185466</ArticleId></ArticleIdList></Reference><Reference><Citation>McClain M.E., Hackett A.J., Madin S.H. Plaque Morphology and Pathogenicity of Vesicular Exanthema Virus. Science. 1958;127:1391–1392. doi: 10.1126/science.127.3311.1391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.127.3311.1391</ArticleId><ArticleId IdType="pubmed">13555896</ArticleId></ArticleIdList></Reference><Reference><Citation>Debbink K., Lindesmith L.C., Ferris M.T., Swanstrom J., Beltramello M., Corti D., Lanzavecchia A., Baric R.S. Within-Host Evolution Results in Antigenically Distinct GII.4 Noroviruses. J. Virol. 2014;88:7244–7255. doi: 10.1128/JVI.00203-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00203-14</ArticleId><ArticleId IdType="pmc">PMC4054459</ArticleId><ArticleId IdType="pubmed">24648459</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasser R., Cloutier M., Prévost J., Fink C., Ducas É., Ding S., Dussault N., Landry P., Tremblay T., Laforce-Lavoie A., et al. Major Role of IgM in the Neutralizing Activity of Convalescent Plasma against SARS-CoV-2. Cell Rep. 2021;34:108790. doi: 10.1016/j.celrep.2021.108790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108790</ArticleId><ArticleId IdType="pmc">PMC7874916</ArticleId><ArticleId IdType="pubmed">33596407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober C., Manni S., Wolff S., Barnes T., Mukherjee S., Vogel T., Hoenig L., Vogel P., Hahn A., Gerlach M., et al. IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma Pools. PLoS ONE. 2022;17:e0262162. doi: 10.1371/journal.pone.0262162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262162</ArticleId><ArticleId IdType="pmc">PMC8726489</ArticleId><ArticleId IdType="pubmed">34982806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z., Xie X., Hinton P.R., Liu X., Ye X., Muruato A.E., Ng D.C., Biswas S., Zou J., Liu Y., et al. Nasal Delivery of an IgM Offers Broad Protection from SARS-CoV-2 Variants. Nature. 2021;595:718–723. doi: 10.1038/s41586-021-03673-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03673-2</ArticleId><ArticleId IdType="pmc">PMC8742224</ArticleId><ArticleId IdType="pubmed">34082438</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., Katzourakis A. The Evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361–379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng C., Evans J.P., King T., Zheng Y.M., Oltz E.M., Whelan S.P.J., Saif L.J., Peeples M.E., Liu S.L. SARS-CoV-2 Spreads through Cell-to-Cell Transmission. Proc. Natl. Acad. Sci. USA. 2022;119:e2111400119. doi: 10.1073/pnas.2111400119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2111400119</ArticleId><ArticleId IdType="pmc">PMC8740724</ArticleId><ArticleId IdType="pubmed">34937699</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli A.M., Peacock T.P., Thorne L.G., Harvey W.T., Hughes J., de Silva T.I., Peacock S.J., Barclay W.S., de Silva T.I., Towers G.J., et al. SARS-CoV-2 Variant Biology: Immune Escape, Transmission and Fitness. Nat. Rev. Microbiol. 2023;21:162–177. doi: 10.1038/s41579-022-00841-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00841-7</ArticleId><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer D.K., Forero A. Mechanisms of Antiviral Immune Evasion of SARS-CoV-2. J. Mol. Biol. 2022;434:167265. doi: 10.1016/j.jmb.2021.167265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2021.167265</ArticleId><ArticleId IdType="pmc">PMC8457632</ArticleId><ArticleId IdType="pubmed">34562466</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadbent L., Bamford C.G.G., Campos G.L., Manzoor S., Courtney D., Ali A., Touzelet O., McCaughey C., Mills K., Power U.F. An Endogenously Activated Antiviral State Restricts SARS-CoV-2 Infection in Differentiated Primary Airway Epithelial Cells. PLoS ONE. 2022;17:e0266412. doi: 10.1371/journal.pone.0266412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266412</ArticleId><ArticleId IdType="pmc">PMC9015133</ArticleId><ArticleId IdType="pubmed">35436306</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton M.J., Ort J.T., McBride R., Swanson N.J., Wilson J., Awofolaju M., Furey C., Greenplate A.R., Drapeau E.M., Pekosz A., et al. Antigenic and Virological Properties of an H3N2 Variant That Continues to Dominate the 2021–22 Northern Hemisphere Influenza Season. Cell Rep. 2022;39:110897. doi: 10.1016/j.celrep.2022.110897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110897</ArticleId><ArticleId IdType="pmc">PMC9153083</ArticleId><ArticleId IdType="pubmed">35649381</ArticleId></ArticleIdList></Reference><Reference><Citation>Manon L., Annelies S., Valerie R., Talitha B., Inga N., Winston C., Mohammed B., Bart V., Stefan P., Lieve N. Hemagglutinin Cleavability, Acid Stability, and Temperature Dependence Optimize Influenza B Virus for Replication in Human Airways. J. Virol. 2019;94:10.1128/jvi.01430-19. doi: 10.1128/jvi.01430-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01430-19</ArticleId><ArticleId IdType="pmc">PMC6912116</ArticleId><ArticleId IdType="pubmed">31597759</ArticleId></ArticleIdList></Reference><Reference><Citation>Otter C.J., Fausto A., Tan L.H., Khosla A.S., Cohen N.A., Weiss S.R. Infection of Primary Nasal Epithelial Cells Differentiates among Lethal and Seasonal Human Coronaviruses. Proc. Natl. Acad. Sci. USA. 2023;120:e2218083120. doi: 10.1073/pnas.2218083120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2218083120</ArticleId><ArticleId IdType="pmc">PMC10104492</ArticleId><ArticleId IdType="pubmed">37023127</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui K.P.Y., Ng K.-C., Ho J.C.W., Yeung H.-W., Ching R.H.H., Gu H., Chung J.C.K., Chow V.L.Y., Sit K.-Y., Hsin M.K.Y., et al. Replication of SARS-CoV-2 Omicron BA.2 Variant in Ex Vivo Cultures of the Human Upper and Lower Respiratory Tract. EBioMedicine. 2022;83:104232. doi: 10.1016/j.ebiom.2022.104232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104232</ArticleId><ArticleId IdType="pmc">PMC9387351</ArticleId><ArticleId IdType="pubmed">35988466</ArticleId></ArticleIdList></Reference><Reference><Citation>Stauft C.B., Sangare K., Wang T.T. Differences in New Variant of Concern Replication at Physiological Temperatures In Vitro. J. Infect. Dis. 2023;227:202–205. doi: 10.1093/infdis/jiac264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac264</ArticleId><ArticleId IdType="pmc">PMC9384407</ArticleId><ArticleId IdType="pubmed">35759271</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Ye Z.-W., Liang R., Tang K., Zhang A.J., Lu G., Ong C.P., Man Poon V.K., Chan C.C.-S., Mok B.W.-Y., et al. Pathogenicity, Transmissibility, and Fitness of SARS-CoV-2 Omicron in Syrian Hamsters. Science. 2022;377:428–433. doi: 10.1126/science.abn8939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn8939</ArticleId><ArticleId IdType="pubmed">35737809</ArticleId></ArticleIdList></Reference><Reference><Citation>Amato K.A., Haddock L.A., Braun K.M., Meliopoulos V., Livingston B., Honce R., Schaack G.A., Boehm E., Higgins C.A., Barry G.L., et al. Influenza A Virus Undergoes Compartmentalized Replication In Vivo Dominated by Stochastic Bottlenecks. Nat. Commun. 2022;13:3416. doi: 10.1038/s41467-022-31147-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31147-0</ArticleId><ArticleId IdType="pmc">PMC9197827</ArticleId><ArticleId IdType="pubmed">35701424</ArticleId></ArticleIdList></Reference><Reference><Citation>Farjo M., Koelle K., Martin M.A., Gibson L.L., Walden K.K.O., Rendon G., Fields C.J., Alnaji F.G., Gallagher N., Luo C.H., et al. Within-Host Evolutionary Dynamics and Tissue Compartmentalization during Acute SARS-CoV-2 Infection. J. Virol. 2024;98:e01618-23. doi: 10.1128/jvi.01618-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01618-23</ArticleId><ArticleId IdType="pmc">PMC10805032</ArticleId><ArticleId IdType="pubmed">38174928</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>